Tamoxifen related chorioretinal structural changes

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Polychemotherapy for early breast cancer: an overview of the ranomised trials. Early breast cancer trialists’ collaborative group. Lancet. 1998; 352(9132):930–942.
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists’ collaborative group. Lancet. 1998; 351(9114):1451–1467.
   PubMed Web of Science ®Google Scholar
• Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from international breast cancer study group trials. Cancer. 2006;106(3):505–513. doi: 10.1002/cncr.21651
   PubMed Web of Science ®Google Scholar
• Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond). 1999; 13(6):729–733. doi: 10.1038/eye.1999.217
   PubMedGoogle Scholar
• Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997;11(3):295–297. doi: 10.1038/eye.1997.64
   PubMedGoogle Scholar
• Bernstein PS, DellaCroce JT. Diagnostic & therapeutic challenges. Tamoxifen toxicity. Retina. 2007; 27(7):982–988. doi: 10.1097/IAE.0b013e31813c69f7
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000; 60(2):167–172. doi: 10.1023/a:1006342300291
   PubMed Web of Science ®Google Scholar
• Koulisis N, Moysidis SN, Olmos de Koo LC, et al. The tipping point: Tamoxifen toxicity, Central serous chorioretinopathy, and the role of estrogen and its receptors. Am J Ophthalmol Case Rep. 2016; 3:8–13. doi: 10.1016/j.ajoc.2016.05.004
   PubMedGoogle Scholar
• Ersoz MG, Arf S, Karacorlu M, et al. Pachychoroid pigment epitheliopathy associated with tamoxifen. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(10):838–842. doi: 10.3928/23258160-20170928-10
   PubMed Web of Science ®Google Scholar
• Bolukbasi S, Kandemir Gursel O, Cakir A, et al. Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography. Cutan Ocul Toxicol. 2020; 39(2):115–121. doi: 10.1080/15569527.2020.1734816
   PubMed Web of Science ®Google Scholar
• Crisóstomo S, Vieira L, Cardigos J, et al. Tamoxıfen-ınduced chorıoretınal changes: an optical coherence tomography and optical coherence tomography angiography study. Retina. 2020; 40(6):1185–1190. doi: 10.1097/IAE.0000000000002533
   PubMed Web of Science ®Google Scholar
• Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment ­epitheliopathy. Retina. 2013; 33(8):1659–1672. doi: 10.1097/IAE.0b013e3182953df4
   PubMed Web of Science ®Google Scholar
• Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011; 36(10):867–885. doi: 10.3109/02713683.2011.594202
   PubMed Web of Science ®Google Scholar
• Giddabasappa A, Bauler M, Yepuru M, et al. 17-β Estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor-β. Invest Ophthalmol Vis Sci. 2010; 51(10):5278–5287. doi: 10.1167/iovs.10-5316
   PubMed Web of Science ®Google Scholar
• Munaut C, Lambert V, Noël A, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001; 85(7):877–882. doi: 10.1136/bjo.85.7.877
   PubMed Web of Science ®Google Scholar
• Wickham LA, Gao J, Toda I, et al. Identification of androgen, ­estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand. 2000; 78(2):146–153. doi: 10.1034/j.1600-0420.2000.078002146.x
   PubMedGoogle Scholar
• Ogueta SB, Schwartz SD, Yamashita CK, et al. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci. 1999; 40(9):1906–1911.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kobayashi H, Ueda M, et al. Estrogen receptor expression in bovine and rat retinas. Invest Ophthalmol Vis Sci. 1998; 39(11):2105–2110.
   PubMed Web of Science ®Google Scholar
• Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified airlie house classification. ETDRS report number 10. Early treatment diabetic retinopathy study research group. Ophthalmology. 1991; 98(5 Suppl):786–806.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gupta P, Tan KA, et al. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci Rep. 2016; 6:21090. doi: 10.1038/srep21090
   PubMed Web of Science ®Google Scholar
• Lazzaroni F, Scorolli L, Pizzoleo CF, et al. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol. 1998; 236(9):669–673. doi: 10.1007/s004170050139
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Karagoz A, Altin Ekin M. Ocular findings in breast cancer patients using tamoxifen. Cutan Ocul Toxicol. 2015; 34(1):16–20. doi: 10.3109/15569527.2014.888078
   PubMed Web of Science ®Google Scholar
• Salomão SR, Watanabe SE, Berezovsky A, et al. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res. 2007; 32(4):345–352. doi: 10.1080/02713680701229638
   PubMed Web of Science ®Google Scholar
• Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998; 125(4):493–501. doi: 10.1016/s0002-9394(99)80190-1
   PubMed Web of Science ®Google Scholar
• Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in Central serous chorioretinopathy. Br J Ophthalmol. 2007; 91(1):118–119. doi: 10.1136/bjo.2006.098277
   PubMed Web of Science ®Google Scholar
• Nudleman E, Witmer MT, Kiss S, et al. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina. 2014;34(10):2128–2132. doi: 10.1097/IAE.0000000000000198
   PubMed Web of Science ®Google Scholar
• Liang ZQ, Huang LZ, Qu JF, et al. Association between endogenous cortisol level and the risk of Central serous chorioretinopathy: a meta-analysis. Int J Ophthalmol. 2018; 11(2):296–300. doi: 10.18240/ijo.2018.02.19
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Stavreus Evers A, et al. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. Climacteric. 2014; 17(1):48–54. doi: 10.3109/13697137.2013.800039
   PubMed Web of Science ®Google Scholar
• Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005; 140(4):757–758. doi: 10.1016/j.ajo.2005.04.042
   PubMed Web of Science ®Google Scholar
• Mäenpää H, Mannerström M, Toimela T, et al. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 2002; 91(3):116–122. doi: 10.1034/j.1600-0773.2002.910305.x
   PubMedGoogle Scholar
• Goldman D. Müller glial cell reprogramming and retina regeneration. Nat Rev Neurosci. 2014; 15(7):431–442. doi: 10.1038/nrn3723
   PubMed Web of Science ®Google Scholar
• Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981; 88(1):89–93. doi: 10.1016/s0161-6420(81)35071-4
   PubMed Web of Science ®Google Scholar
• Dyer MA, Cepko CL. Control of müller glial cell proliferation and activation following retinal injury. Nat Neurosci. 2000; 3(9):873–880. doi: 10.1038/78774
   PubMed Web of Science ®Google Scholar
• Sodhi M, Yeung SN, Maberley D, et al. Risk of ocular adverse events With Taxane-Based chemotherapy. JAMA Ophthalmol. 2022; 140(9):880–884. doi: 10.1001/jamaophthalmol.2022.3026
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi: 10.1016/S0140-6736(12)61963-1
   PubMed Web of Science ®Google Scholar